Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial
Benzinga Newsdesk 4 months ago
BiotechNewsGeneral
Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trialCompany to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET
Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial
Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET